Infection-Myelosuppression Study Group & Resource Center
Study Group Goals, Mission and Annual Meeting Minutes
Chair Contacts
Chair: Bernardo L Rapoport at brapoport@icon.co.za or brapoport@rapoport.co.za
Co-chair:Harry Raftopoulis, MD at hraftopo@nshs.edu
Related Publications
1: Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M,Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C
European Organisation for Research and Treatment of Cancer (EORTC)
Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party.
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
Eur J Cancer. 2006 Jun 5; [Epub ahead of print]
PMID: 16750358 [PubMed - as supplied by publisher]
2: Crawford J.
Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia.
Oncology (Williston Park). 2006 Apr;20(5 Suppl 4):22-8.
PMID: 16736985 [PubMed - in process]
3: Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L,Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA,Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ,Wozniak AJ, Wolff AC.
2006 update of recommendations for the use of white blood cell growth factors:an evidence-based clinical practice guideline.
J Clin Oncol. 2006 Jul 1;24(19):3187-205. Epub 2006 May 8.
PMID: 16682719 [PubMed - indexed for MEDLINE]
